| Castleman's disease: from basic mechanisms to molecular therapeutics HE El‐Osta, R Kurzrock The Oncologist 16 (4), 497-511, 2011 | 234 | 2011 |
| Epigenetics in non-small cell lung cancer: from basics to therapeutics J Ansari, RE Shackelford, H El-Osta Translational lung cancer research 5 (2), 155, 2016 | 168 | 2016 |
| BRAF mutations in advanced cancers: clinical characteristics and outcomes H El-Osta, G Falchook, A Tsimberidou, D Hong, A Naing, K Kim, S Wen, ... PloS one 6 (10), e25806, 2011 | 120 | 2011 |
| Effects of clopidogrel on soluble CD40 ligand and on high-sensitivity C-reactive protein in patients with stable coronary artery disease RR Azar, R Kassab, A Zoghbi, S Aboujaoudé, H El-Osta, P Ghorra, ... American heart journal 151 (2), 521. e1-521. e4, 2006 | 117 | 2006 |
| Successful treatment of Castleman's disease with interleukin-1 receptor antagonist (Anakinra) H El-Osta, F Janku, R Kurzrock Molecular cancer therapeutics 9 (6), 1485-1488, 2010 | 101 | 2010 |
| Modulating lysosomal function through lysosome membrane permeabilization or autophagy suppression restores sensitivity to cisplatin in refractory non-small-cell lung cancer cells M Circu, J Cardelli, M Barr, K O'Byrne, G Mills, H El-Osta PLoS ONE 12 (9), e0184922, 2017 | 87 | 2017 |
| Outcomes of research biopsies in phase I clinical trials: the MD anderson cancer center experience H El‐Osta, D Hong, J Wheler, S Fu, A Naing, G Falchook, M Hicks, S Wen, ... The oncologist 16 (9), 1292-1298, 2011 | 74 | 2011 |
| Histiocytic sarcoma as a secondary malignancy: pathobiology, diagnosis, and treatment J Ansari, AR Naqash, R Munker, H El‐Osta, S Master, JD Cotelingam, ... European journal of haematology 97 (1), 9-16, 2016 | 66 | 2016 |
| Predictors for clinical benefit of immune checkpoint inhibitors in advanced non-small-cell lung cancer: a meta-analysis H El-Osta, S Jafri Immunotherapy 11 (3), 189-199, 2019 | 59 | 2019 |
| Endobronchial Ultrasound for Nodal Staging of Patients with Non–Small-Cell Lung Cancer with Radiologically Normal Mediastinum. A Meta-Analysis H El-Osta, P Jani, A Mansour, P Rascoe, S Jafri Annals of the American Thoracic Society 15 (7), 864-874, 2018 | 45 | 2018 |
| Lung carcinoma associated with excessive eosinophilia H El-Osta, P El-Haddad, N Nabbout Journal of clinical oncology 26 (20), 3456-3457, 2008 | 41 | 2008 |
| Immune checkpoint inhibitors: the new frontier in non-small-cell lung cancer treatment H El-Osta, K Shahid, GM Mills, P Peddi OncoTargets and therapy, 5101-5116, 2016 | 36 | 2016 |
| Personalized treatment options for ALK-positive metastatic non-small-cell lung cancer: potential role for Ceritinib H El-Osta, R Shackelford Pharmacogenomics and personalized medicine, 145-154, 2015 | 30 | 2015 |
| A novel high content imaging-based screen identifies the anti-helminthic niclosamide as an inhibitor of lysosome anterograde trafficking and prostate cancer cell invasion ML Circu, SS Dykes, J Carroll, K Kelly, F Galiano, A Greer, J Cardelli, ... PloS one 11 (1), e0146931, 2016 | 29 | 2016 |
| Mitochondrial ROS and apoptosis H El-Osta, ML Circu Mitochondrial Mechanisms of Degeneration and Repair in Parkinson's Disease, 1-23, 2016 | 26 | 2016 |
| Unexplained hemopericardium as a presenting feature of primary cardiac angiosarcoma: a case report and a review of the diagnostic dilemma HE El-Osta, YS Yammine, BM Chehab, AS Fields, DF Moore Jr, BI Mattar Journal of Thoracic Oncology 3 (7), 800-802, 2008 | 26 | 2008 |
| Major stressful life events and risk of developing lung cancer: a case-control study SH Jafri, F Ali, A Mollaeian, S Mojiz Hasan, R Hussain, B Akkanti, ... Clinical Medicine Insights: Oncology 13, 1179554919835798, 2019 | 17 | 2019 |
| Rituximab-induced acute thrombocytopenia: an underappreciated entity H El-Osta, B Nair Leukemia & Lymphoma 54 (12), 2736-2737, 2013 | 17 | 2013 |
| Predictors of benefits from frontline chemoimmunotherapy in stage IV non-small-cell lung cancer: a meta-analysis HE El-Osta, FE Mott, BM Burt, DY Wang, AL Sabichi Oncoimmunology 8 (12), e1665974, 2019 | 15 | 2019 |
| Brief report: canadian cancer trials group IND. 227: A phase 2 randomized study of pembrolizumab in patients with advanced Malignant pleural mesothelioma (NCT02784171) MC Piccirillo, Q Chu, P Bradbury, W Tu, CH Coschi, F Grosso, M Florescu, ... Journal of Thoracic Oncology 18 (6), 813-819, 2023 | 13 | 2023 |
